It's B Corp Month

We are proud to be a B Corporation.

This March is B Corp month – a whole month dedicated to celebrating businesses who are doing things differently and driving change and raising awareness in a globally coordinated social media effort to celebrate B Corps.

In 2017, we became a Certified B Corp. Being the first Chemical/ Pharmaceutical Company integrating an innovative community of companies that use the power of business to solve social and environmental problems.

Being a B Corporation means that to ensure our long‑term viability we will contribute positively to economic, environmental, and social sustainability.

As a Certified B Corporation^TM we want to contribute to redefine success in business, meeting the highest standards of social and environmental performance, setting our Team Members for success and personal satisfaction, and aspiring to use the power of markets to solve social and environmental problems. Collectively, B Corps lead a growing global movement of people using business as a force for good^TM.

We are proud to be a B Corporation.

Learn more about Hovione being a B Corporation

https://www.bcorporation.net/

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net

Press Clipping

News Medical Life Sciences, 1 June 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026

Browser not supported

Press Room

It's B Corp Month

We are proud to be a B Corporation.

Also in the Press Room

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Prestigious Caixa +Mundo Award named in honor of Diane Villax

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

Also in Events

CPHI China 2026